Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Average Price Target from Analysts

Shares of Neurogene Inc. (NASDAQ:NGNE) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $44.00.

A number of research firms have recently commented on NGNE. Lifesci Capital started coverage on Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Finally, Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th.

Neurogene Stock Up 2.2%

NASDAQ:NGNE opened at $17.38 on Friday. The company’s 50 day moving average is $18.91 and its 200-day moving average is $21.59. Neurogene has a 12 month low of $6.88 and a 12 month high of $37.27. The firm has a market cap of $269.22 million, a price-to-earnings ratio of -4.23 and a beta of 1.59.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.27. Research analysts predict that Neurogene will post -4.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its stake in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the period. PNC Financial Services Group Inc. lifted its stake in Neurogene by 24.7% during the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after purchasing an additional 1,000 shares during the period. ADAR1 Capital Management LLC boosted its holdings in Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after purchasing an additional 1,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the period. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Neurogene in the 4th quarter valued at approximately $66,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.